Adverum Biotech Financials
This page shows Adverum Biotech (ADVM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Adverum Biotech has an operating margin of -13915.9%, meaning the company retains $-13916 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -3581.7% the prior year.
Adverum Biotech's revenue declined 72.2% year-over-year, from $3.6M to $1.0M. This contraction results in a growth score of 0/100.
Adverum Biotech has a moderate D/E ratio of 1.54. This balance of debt and equity financing earns a leverage score of 54/100.
With a current ratio of 5.73, Adverum Biotech holds $5.73 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Adverum Biotech generated -$92.5M in operating cash flow, capex of $388K consumed most of it, leaving -$92.8M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Adverum Biotech passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Adverum Biotech generates $0.71 in operating cash flow (-$92.5M OCF vs -$130.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Adverum Biotech generated $1.0M in revenue in fiscal year 2024. This represents a decrease of 72.2% from the prior year.
Adverum Biotech's EBITDA was -$135.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 9.9% from the prior year.
Adverum Biotech generated -$92.8M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 1.2% from the prior year.
Adverum Biotech reported -$130.9M in net income in fiscal year 2024. This represents a decrease of 7.2% from the prior year.
Adverum Biotech earned $-6.62 per diluted share (EPS) in fiscal year 2024. This represents an increase of 45.3% from the prior year.
Adverum Biotech held $60.7M in cash against $0 in long-term debt as of fiscal year 2024.
Adverum Biotech had 21M shares outstanding in fiscal year 2024. This represents an increase of 105.5% from the prior year.
Adverum Biotech's operating margin was -13915.9% in fiscal year 2024, reflecting core business profitability. This is down 10334.2 percentage points from the prior year.
Adverum Biotech's net profit margin was -13092.7% in fiscal year 2024, showing the share of revenue converted to profit. This is down 9700.6 percentage points from the prior year.
Adverum Biotech invested $77.0M in research and development in fiscal year 2024. This represents a decrease of 0.6% from the prior year.
Adverum Biotech invested $388K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 52.0% from the prior year.
ADVM Income Statement
| Metric | Q3'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0-100.0% | $3.6M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $38.9M+61.5% | $24.1M+40.9% | $17.1M+10.9% | $15.4M+0.9% | $15.3M-26.3% | $20.7M+0.7% | $20.6M-1.3% | $20.9M |
| SG&A Expenses | $9.1M-50.8% | $18.5M+17.2% | $15.8M+14.6% | $13.8M+18.2% | $11.7M-18.5% | $14.3M+6.2% | $13.5M-13.5% | $15.6M |
| Operating Income | -$48.0M-12.7% | -$42.6M-29.5% | -$32.9M-12.7% | -$29.2M-8.4% | -$26.9M+23.1% | -$35.1M-2.9% | -$34.1M-3.7% | -$32.9M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $0 | $0 | $0+100.0% | -$1.1M-6764.7% | $17K-19.0% | $21K+23.5% | $17K |
| Net Income | -$47.7M-16.4% | -$40.9M-34.2% | -$30.5M-12.3% | -$27.1M-10.8% | -$24.5M+26.7% | -$33.4M-2.7% | -$32.5M-2.7% | -$31.7M |
| EPS (Diluted) | $-2.03-3.6% | $-1.96-34.2% | $-1.46 | $-1.65 | $-2.41 | $-3.31-2.5% | $-3.23-2.2% | $-3.16 |
ADVM Balance Sheet
| Metric | Q3'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $72.4M-59.7% | $179.8M-21.7% | $229.6M-8.4% | $250.5M+60.8% | $155.8M-13.3% | $179.6M-20.0% | $224.4M-11.2% | $252.7M |
| Current Assets | $28.9M-78.0% | $131.3M-26.8% | $179.4M-9.9% | $199.1M+93.8% | $102.8M-17.5% | $124.6M-15.3% | $147.1M-12.9% | $168.9M |
| Cash & Equivalents | $26.1M-57.0% | $60.7M-52.4% | $127.3M-14.9% | $149.6M+99.5% | $75.0M-28.8% | $105.4M-5.2% | $111.2M+64.6% | $67.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $128.1M+17.3% | $109.1M+18.4% | $92.2M+6.1% | $86.9M-1.9% | $88.5M-4.1% | $92.4M-14.6% | $108.1M-0.6% | $108.8M |
| Current Liabilities | $44.7M+95.4% | $22.9M+31.2% | $17.5M+5.3% | $16.6M-17.0% | $20.0M-16.6% | $24.0M-39.6% | $39.7M-3.1% | $40.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$55.7M-178.7% | $70.7M-48.5% | $137.4M-16.1% | $163.7M+143.5% | $67.2M-23.0% | $87.3M-24.9% | $116.2M-19.2% | $143.8M |
| Retained Earnings | -$1.2B-13.5% | -$1.1B-7.4% | -$993.7M-3.2% | -$963.2M-2.9% | -$936.0M-2.7% | -$911.5M-3.8% | -$878.1M-3.8% | -$845.6M |
ADVM Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$28.1M+0.5% | -$28.2M-42.4% | -$19.8M+14.6% | -$23.2M-9.0% | -$21.3M+10.8% | -$23.9M-2.9% | -$23.2M-3.7% | -$22.4M |
| Capital Expenditures | $142K+132.8% | $61K+281.3% | $16K-82.2% | $90K-53.1% | $192K-61.2% | $495K+1275.0% | $36K-57.6% | $85K |
| Free Cash Flow | -$28.3M+0.2% | -$28.3M-42.5% | -$19.9M+14.9% | -$23.3M-8.4% | -$21.5M+11.8% | -$24.4M-4.8% | -$23.3M-3.5% | -$22.5M |
| Investing Cash Flow | $1.9M+144.4% | -$4.2M-80.0% | -$2.3M+89.4% | -$22.0M-123.0% | -$9.9M-154.3% | $18.2M-72.8% | $67.0M+211.3% | $21.5M |
| Financing Cash Flow | $9.9M+4041.8% | $239K+306.0% | -$116K-100.1% | $119.9M+72116.9% | $166K+258.1% | -$105K-1412.5% | $8K | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ADVM Financial Ratios
| Metric | Q3'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | -3443.8% | N/A | N/A | N/A | N/A | N/A | -912.6% |
| Net Margin | N/A | -3235.1% | N/A | N/A | N/A | N/A | N/A | -879.8% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -65.8%-43.1pp | -22.8%-9.5pp | -13.3%-2.4pp | -10.8%+4.9pp | -15.7%+2.9pp | -18.6%-4.1pp | -14.5%-2.0pp | -12.5% |
| Current Ratio | 0.65-5.1 | 5.73-4.5 | 10.28-1.7 | 12.01+6.9 | 5.14-0.1 | 5.20+1.5 | 3.71-0.4 | 4.12 |
| Debt-to-Equity | -2.30-3.8 | 1.54+0.9 | 0.67+0.1 | 0.53-0.8 | 1.32+0.3 | 1.06+0.1 | 0.93+0.2 | 0.76 |
| FCF Margin | N/A | -2134.5% | N/A | N/A | N/A | N/A | N/A | -624.9% |
Similar Companies
Frequently Asked Questions
What is Adverum Biotech's annual revenue?
Adverum Biotech (ADVM) reported $1.0M in total revenue for fiscal year 2024. This represents a -72.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Adverum Biotech's revenue growing?
Adverum Biotech (ADVM) revenue declined by 72.2% year-over-year, from $3.6M to $1.0M in fiscal year 2024.
Is Adverum Biotech profitable?
No, Adverum Biotech (ADVM) reported a net income of -$130.9M in fiscal year 2024, with a net profit margin of -13092.7%.
What is Adverum Biotech's earnings per share (EPS)?
Adverum Biotech (ADVM) reported diluted earnings per share of $-6.62 for fiscal year 2024. This represents a 45.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Adverum Biotech's EBITDA?
Adverum Biotech (ADVM) had EBITDA of -$135.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Adverum Biotech's operating margin?
Adverum Biotech (ADVM) had an operating margin of -13915.9% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Adverum Biotech's net profit margin?
Adverum Biotech (ADVM) had a net profit margin of -13092.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Adverum Biotech's free cash flow?
Adverum Biotech (ADVM) generated -$92.8M in free cash flow during fiscal year 2024. This represents a -1.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Adverum Biotech's operating cash flow?
Adverum Biotech (ADVM) generated -$92.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Adverum Biotech's total assets?
Adverum Biotech (ADVM) had $179.8M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Adverum Biotech's capital expenditures?
Adverum Biotech (ADVM) invested $388K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Adverum Biotech spend on research and development?
Adverum Biotech (ADVM) invested $77.0M in research and development during fiscal year 2024.
How many shares does Adverum Biotech have outstanding?
Adverum Biotech (ADVM) had 21M shares outstanding as of fiscal year 2024.
What is Adverum Biotech's current ratio?
Adverum Biotech (ADVM) had a current ratio of 5.73 as of fiscal year 2024, which is generally considered healthy.
What is Adverum Biotech's debt-to-equity ratio?
Adverum Biotech (ADVM) had a debt-to-equity ratio of 1.54 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Adverum Biotech's return on assets (ROA)?
Adverum Biotech (ADVM) had a return on assets of -72.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Adverum Biotech's cash runway?
Based on fiscal year 2024 data, Adverum Biotech (ADVM) had $60.7M in cash against an annual operating cash burn of $92.5M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Adverum Biotech's Piotroski F-Score?
Adverum Biotech (ADVM) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Adverum Biotech's earnings high quality?
Adverum Biotech (ADVM) has an earnings quality ratio of 0.71x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Adverum Biotech?
Adverum Biotech (ADVM) scores 31 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.